![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Merck’s Keytruda Gets Priority Review Status
Merck’s Keytruda Gets Priority Review Status
![](https://www.fdanews.com/ext/resources/test/Merck.gif?t=1434062647&width=430)
The FDA granted priority review for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 immunotherapy used in the treatment of certain cancers.
Merck has more than 10 studies investigating Keytruda in gastrointestinal cancers, including hepatocellular carcinoma.
A humanized monoclonal antibody, Keytruda works by bolstering the body’s ability to detect and combat tumor cells. It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thus activating T-cells.
Upcoming Events
-
21Oct